ChemGenex completes SPP
Tuesday, 14 October, 2008
ChemGenex Pharmaceuticals [ASX: CXS] has completed its share placement program, raising over $13 million to fund the late-stage development of its omacetaxine candidate for chronic myeloid leukaemia.
15.3 million shares were placed during the program, trading at 85 cents each. During the period of the program, CXS shares traded at a high of 83 cents and a low of 72.5 cents.
All shares on offer were purchased. ChemGenex representatives said they were pleased the placement went so well considering the unstable global financial climate.
Scientists uncover how cancer cells hide from immune system
By targeting the RNA helicase known as DDX6, scientists could enable the immune system to...
Vanillin flavouring in vapes may disrupt embryo development
Vanillin — a common flavouring chemical in e-cigarettes — may disrupt the normal...
Heart valve tissues created from stem cells
The breakthrough should help advance our understanding into how human heart valves develop,...
